替加环素在肿瘤治疗领域的研究进展

Anti-tumor activity of tigecycline: a review

摘要:

替加环素 (Tigecycline) 作为一种新型甘氨环素类抗菌药物，其不仅具有抗生素的功能，还具有潜在的抗肿瘤活性。文中对替加环素单独用药、联合用药及其作用机理进行了系统的综述，并进一步阐释了其作为一种线粒体DNA翻译抑制剂，主要通过抑制线粒体蛋白合成和诱发线粒体的功能障碍，进而影响肿瘤细胞的增殖、迁移和侵袭等进程。虽然替加环素单药治疗肿瘤还存在许多争议，但其联合用药的优势还是十分明显的。因此，还需要更多的研究来深度地挖掘替加环素潜在的抗肿瘤活性，争取使其尽早用于肿瘤的临床治疗，有望成为一种廉价高效的抗肿瘤新药物。

关键词:替加环素，抗肿瘤活性，线粒体障碍，联合用药，临床试验

Abstract:

Tigecycline is a novel glycylcycline antibacterial drug, which shows both antibiotic function and anti-tumor activity. This review summarizes the single and combined use of tigecycline for tumor treatment and the underpinning mechanisms. As an inhibitor for mitochondrial DNA translation, tigecycline affects the proliferation, migration, and invasion of tumor cells mainly through inhibiting mitochondrial protein synthesis and inducing mitochondrial dysfunction. Although the effect of tigecycline monotherapy is controversial, the efficacy of combined use of tigecycline is satisfactory. Therefore, it is important to explore the molecular mechanisms underpinning the anti-tumor activity of tigecycline, with the aim to use it as a cheap and effective new anti-tumor drug.

Key words:tigecycline, anti-tumor activity, mitochondrial disorder, drug combination, clinical trial